Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 12/8/2017 11:48:36 AM - Followers: 146 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#5944  Sticky Note Aurinia is no longer just an LN focused Lunacy aka John Galt 11/02/17 03:34:15 PM
#6171   "Biomarker Predicts Lupus Nephritis Flares" moosedogger 12/08/17 11:48:35 AM
#6170   “I think there is a Buy Out coming...just biotech_researcher 12/08/17 10:22:44 AM
#6169   I think there is a Buy Out coming...just greggors 12/08/17 10:01:42 AM
#6168   139 sites. LivingTheDream 12/08/17 09:54:48 AM
#6167   That ignore button works wonders! the gipper 12/08/17 08:40:51 AM
#6166   Dry Eye- Imprimis Launches 99-Cent Generic Drug To biotech_researcher 12/08/17 06:09:34 AM
#6165   From Forbes heldnova 12/08/17 03:03:03 AM
#6164   Of course if you waited more than 30 heldnova 12/08/17 02:41:02 AM
#6163   It is my opinion that your loss would heldnova 12/08/17 02:01:05 AM
#6162   That’s smart!! Hotrodder1 12/07/17 12:21:41 PM
#6161   Nothing more than washing shares. rumrunner528 12/07/17 11:39:39 AM
#6160   Nothing more than washing shares. In 31 days Easymoneyman00 12/06/17 08:11:49 PM
#6159   On a serious note, are you still invested Jesspro 12/06/17 07:45:15 PM
#6158   Jess, only cervelo can tell you if it biotech_researcher 12/06/17 07:20:38 PM
#6157   Thanks BR... Jesspro 12/06/17 07:18:08 PM
#6156   You obviously lack a great deal of understanding. cervelo 12/06/17 06:29:50 PM
#6155   Yes BR, I have a question for you. Jesspro 12/06/17 05:41:03 PM
#6154   That’s a fact! Hotrodder1 12/06/17 02:43:26 PM
#6153   What An Awesome Time-Of-Day To Buy! ThePromise247 12/06/17 02:05:33 PM
#6152   The rumblings on the street is the Aurinia biotech_researcher 12/06/17 01:02:41 PM
#6151   Jesspro, do you have any questions for me???? biotech_researcher 12/06/17 11:40:30 AM
#6150   This is a high volume sell off so biotech_researcher 12/06/17 11:38:01 AM
#6149   All you have to know is it is biotech_researcher 12/06/17 10:22:21 AM
#6148   Lot of knowledge coming through today on this board! Newbie1421 12/06/17 10:20:00 AM
#6147   Now, $4.80 on the bid.... biotech_researcher 12/06/17 08:36:59 AM
#6146   It must be fun to reply to your alias! SvsB 12/05/17 10:10:16 PM
#6145   speculative Indeed. cervelo 12/05/17 08:42:27 PM
#6144   Ridiculous. Now in $4’s biotech_researcher 12/05/17 04:03:47 PM
#6143   Too close to $5.. biotech_researcher 12/05/17 03:58:42 PM
#6142   BR, any news?. I worry when you are quiet. Jesspro 12/05/17 03:46:29 AM
#6141   137 sites. LivingTheDream 12/04/17 12:26:12 PM
#6140   impressive, market continues to run and we remain cervelo 12/04/17 10:11:46 AM
#6138   For anyone interested in the true picture for Lunacy aka John Galt 12/01/17 05:21:49 PM
#6137   Actually he's not giving a story. Just the tiv111 12/01/17 05:16:29 PM
#6136   I suspect they are not buying the Glicky biotech_researcher 12/01/17 04:43:48 PM
#6135   Institutional ownership of AUPH has plummeted big time. biotech_researcher 12/01/17 04:42:28 PM
#6134   hehehehe. Good board.. Good data on AUPH and Glicky.. biotech_researcher 12/01/17 08:33:37 AM
#6131   Like! lugan 11/30/17 10:47:52 PM
#6130   mfund, unfortunately, the author of that SA article biotech_researcher 11/30/17 03:26:03 PM
#6129   New SA article, mfun98 11/29/17 11:09:09 PM
#6128   Vidpok45's last message was in a Jailhouse group sonicty28 11/29/17 03:47:29 PM
#6127   Well, down from $7.05 to $5.13 in a biotech_researcher 11/29/17 01:13:57 PM
#6126   market running up and well we are?????????speculative cervelo 11/29/17 01:03:20 PM
#6125  Restored The rumblings on the street is the Aurinia biotech_researcher 11/29/17 12:45:08 PM
#6124   SA-"3 Reasons To Buy Aurinia Pharmaceuticals" >>> Whether biotech_researcher 11/28/17 03:39:57 PM
#6123   They are throwing AUPH under the bus.......again... biotech_researcher 11/28/17 02:19:26 PM
#6122   SA-"3 Reasons To Buy Aurinia Pharmaceuticals" moosedogger 11/24/17 09:35:25 PM
#6120   tiv111, we both know it is not that biotech_researcher 11/22/17 06:27:25 PM
#6119   The FDA didn't even ask auph to prove tiv111 11/22/17 04:39:09 PM
#6118   Right You Are Tiv111 ThePromise247 11/22/17 03:42:56 PM